BioCentury | Jul 14, 2017
Strategy

Back to Ipsen’s roots

...Inspiration’s Chapter 11 auction process. In 2013, IB1001 and two preclinical programs were sold to Cangene...
BioCentury | Apr 7, 2017
Company News

Emergent BioSolutions, HHS infectious news

...its contract with HHS’s Biomedical Advanced Research and Development Authority (BARDA) to manufacture and deliver botulism antitoxin heptavalent (BAT)...
...years. Emergent did not respond to inquiries. Emergent gained BAT through its 2014 acquisition of Cangene...
...Health and Human Services , Washington, D.C. Business: Infectious Meghan Sullivan Emergent BioSolutions Biomedical Advanced Research and Development Authority Botulism antitoxin heptavalent (BAT)...
BioCentury | Sep 14, 2015
Company News

Emergent BioSolutions cancer, hematology news

...health threats to civilian and military customers. Its approved products include anthrax vaccine BioThrax and Botulism antitoxin heptavalent (BAT)...
BioCentury | Mar 30, 2015
Clinical News

Anthrasil anthrax immune globulin IV regulatory update

...Drug status for the indication. Emergent gained rights to the product through its acquisition of Cangene...
BioCentury | Mar 26, 2015
Company News

Emergent's anthrax treatment gets FDA nod

...Orphan Drug status from FDA. Emergent gained rights to the product through its acquisition of Cangene...
BioCentury | Jan 15, 2015
Finance

Consortia cross-talk

...a vaccine to induce broadly neutralizing antibodies against HIV 2014 Viral Hemorrhagic Fever Immunotherapeutic Consortium Cangene...
BioCentury | Aug 18, 2014
Company News

Emergent BioSolutions, U.S. Centers for Disease Control and Prevention infectious news

...the total contract value to $36.6 million. Emergent gained VIGIV through its February acquisition of Cangene...
BioCentury | Aug 11, 2014
Clinical News

Anthrax immune globulin IV regulatory update

...a solution of human polyclonal antibodies that target anthrax toxins - through its acquisition of Cangene...
BioCentury | Aug 8, 2014
Company News

Emergent submits BLA for anthrax treatment

...a solution of human polyclonal antibodies that target anthrax toxins -- through its acquisition of Cangene...
BioCentury | Mar 31, 2014
Company News

Emergent BioSolutions, Mapp Biopharmaceutical, Zalgen Labs, Ben-Gurion University of the Negev, NIH, Public Health Agency of Canada, Scripps Research Institute,

...performing industrial-level expression of antibodies, Zalgen is helping to generate antibodies against the arenaviruses, and Cangene...
Items per page:
1 - 10 of 212